We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.6M
AUM Growth
-$2.33B
Cap. Flow
-$744M
Cap. Flow %
-28,550.23%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 6.33%
2 Energy 0.47%
3 Consumer Discretionary 0.36%
4 Industrials 0.15%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBSE
301
PUT
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-1
Closed -$487K
CLVS
302
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-1,998
Closed -$8.27M
CLVS
303
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-20,000
Closed -$828K
CLVS
304
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-206
Closed -$853K
EPZM
305
CALL
DELISTED
Epizyme, Inc
EPZM
– –
-154
Closed -$479K
EPZM
306
DELISTED
Epizyme, Inc
EPZM
– –
-48,790
Closed -$1.52M
ADXS
307
DELISTED
Advaxis Inc
ADXS
– –
-1,267
Closed -$60K
ADXS
308
PUT
DELISTED
Advaxis Inc
ADXS
– –
-67
Closed -$315K
GWPH
309
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-188
Closed -$2.02M
PGNX
310
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-490
Closed -$211K
PGNX
311
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-365,186
Closed -$1.57M
PGNX
312
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-117
Closed -$50K
MDCO
313
DELISTED
Medicines Co
MDCO
– –
-7,948
Closed -$202K
IPCI
314
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-31,400
Closed -$905K
TSRO
315
PUT
DELISTED
TESARO, Inc.
TSRO
– –
-500
Closed -$1.56M
ADXSW
316
DELISTED
Advaxis Inc Warrants
ADXSW
– –
-45,354
Closed -$46K
ANTH
317
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-56,000
Closed -$1.18M
OCRX
318
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-151,358
Closed -$1.16M
AEGR
319
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-2,700
Closed -$8.66M
KYTH
320
CALL
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-300
Closed -$1.15M
SLXP
321
PUT
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-189
Closed -$2.33M
CBST
322
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-18,086
Closed -$1.26M
CBST
323
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-603
Closed -$421M
AVNR
324
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-434,000
Closed -$2.96M
ITMN
325
CALL
DELISTED
INTERMUNE INC
ITMN
– –
-1,235
Closed -$5.45M
10 11 12
13
14

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6M, down 100% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $744M in Q3 2014, closing 85 positions and reducing 62 holdings. Its most notable exit was Weyerhaeuser, an estimated $64.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Acadia Healthcare worth $16.4K.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4K.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6M portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value fell 100% quarter-over-quarter to $2.6M.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.